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in any medium, provided the original work is properly citeLeukaemia-propagating cells are more frequent in high-risk acute B lympho-
blastic leukaemia than in many malignancies that follow a hierarchical cancer
stem cell model. It is unclear whether this characteristic can be more universally
applied to patients from non-‘high-risk’ sub-groups and across a broad range of
cellular immunophenotypes. Here, we demonstrate in a wide range of primary
patient samples and patient samples previously passaged through mice that
leukaemia-propagating cells are found in all populations defined by high or low
expression of the lymphoid differentiation markers CD10, CD20 or CD34. The
frequency of leukaemia-propagating cells and their engraftment kinetics do
not differ between these populations. Transcriptomic analysis of CD34high and
CD34low blasts establishes their difference and their similarity to comparable
normal progenitors at different stages of B-cell development. However, consist-
ent with the functional similarity of these populations, expression signatures
characteristic of leukaemia propagating cells in acute myeloid leukaemia fail to
distinguish between the different populations. Together, these findings suggest
that there is no stem cell hierarchy in acute B lymphoblastic leukaemia.INTRODUCTION
Based on the pioneering work by Till and McCulloch (Till &
McCulloch, 1961), normal haematopoiesis is known to befor Cancer Research,
Tyne Hospitals NHS
, Erasmus MC-Sophia
r Schleswig-Holstein,
niversity, Newcastle
þ44 191 28 24724;
ematology, Oncology
ter Regensburg,
Ltd on behalf of EMBO. This
C BY 3.0), which permits u
d.organized in a hierarchical fashion with a small number of
multipotent stem cells maintaining all haematopoietic lineages.
Similar to normal haematopoiesis, early xenotransplantation
studies demonstrated that only a minority of immature blasts
were able to initiate and propagate human acute myeloid
leukaemia (AML) in immunodeficient mice (Bonnet & Dick,
1997; Lapidot et al, 1994). Subsequent studies have confirmed
that AML is indeed maintained by rare, specialized and
phenotypically defined leukaemia propagating cells (LPCs)
(Goardon et al, 2011; Hope et al, 2004), even if these populations
are more diverse in phenotype than originally suggested
(Taussig et al, 2010).
This hierarchical cancer stem cell model has been explored in
other cancer types using similar xenotransplantation models
(Bomken et al, 2010). Many, including breast (Al-Hajj et al,
2003), brain (Hemmati et al, 2003; Singh et al, 2003), colon
(Dieter et al, 2011; O’Brien et al, 2007; Ricci-Vitiani et al, 2007)
and lung cancer (Eramo et al, 2008; Ho et al, 2007), appear to
follow a similar model. However, the hierarchical stem cellis an open access article under
se, distribution and reproduction
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Klaus Rehe et al.model may not fit all tumours. Notably, studies with melanoma
cells have shown that one in four cells, irrespective of their
immunophenotype, possess the ability to propagate the
tumour (Quintana et al, 2008, 2010). Therefore, the biology
of tumour-propagating cells may vary between different
malignancies. As shown in chronic myeloid leukaemia,
secondary events during malignant progression may lead to
acquisition or expansion of the cancer stem cell phenotype in
malignant cells ‘downstream’ of the cell of origin (Jamieson
et al, 2004). Therefore, stem cell phenotypes and frequencies
may also change during tumour development and progression,
consistent with the model of clonal evolution (Anderson et al,
2011; Notta et al, 2011).
In our previous work, we have challenged the hierarchical
stem cell model for acute B lymphoblastic leukaemia (B-ALL) by
demonstrating that phenotypically diverse blasts irrespective
of the expression of the B-cell marker CD19 and the stem
cell marker CD34 are able to re-establish the leukaemia in
immunodeficient mice (le Viseur et al, 2008). However, key
questions remained to be addressed. Here, we demonstrate that
our model is more widely applicable to B-ALL by investigating
different blast populations identified by the use of additional
B-cell maturation markers, a wider range of ALL subtypes and,
most importantly, engraftment of primary samples that have not
been previously passaged through mice. For the first time, we
provide quantitative data on the frequency of LPCs in different
B-ALL subpopulations. We show that blasts with leukaemia-
propagating capability are present at similar frequencies in all
populations tested and re-grow the leukaemia with similar
kinetics. In keeping with a lack of a hierarchy and the potential
of all populations to propagate the leukaemia, self-renewal
signatures derived from AML and normal haematopoietic stem
cells fail to distinguish between the different ALL blast cell
populations.Figure 1. B-cell differentiation markers and engraftment potential.
A. Expression of the cell surface antigens CD10, CD19, CD20 and CD34 during
normal human B-cell development (van Zelm et al, 2005).
B. Percentage of engrafting primary patient and primograft samples for
the different populations (CD10low/high, CD20low/high, CD34low/high).
Black bars provide the data for primary and white bars for primograft
samples.
C. Weighted mean of engraftment in mice transplanted with at least 1000
blasts sorted for CD10, CD20 or CD34 expression. The analysis takes into
account that different numbers of mice were transplanted with cells from
different samples. For data of engraftment of mice transplanted with cells
sorted for expression of CD10 and CD20, see also Supporting Information
Tables S1 and S2. The CD34 data are taken from the limiting dilutions
experiments (Table 2) and include only the mice transplanted with
1000 cells.RESULTS
Immunophenotypic diversity and malleability of leukaemia-
propagating cells
In our previous experiments, we had shown that phenotypically
diverse ALL blasts, mainly characterized by expression of
CD19 and CD34, are able to propagate the human leukaemia in
immunodeficient mice (le Viseur et al, 2008). One question
that arose from these results was whether this was a generic
finding indicating the absence of a stem cell hierarchy in B-cell
precursor ALL or whether other candidate B-cell markers
would allow enrichment of leukaemia-propagating activity.
We therefore tested CD10 and CD20, surface molecules that are
expressed in a maturation-dependent fashion during normal
B-cell development (Fig 1) (van Zelm et al, 2005). Importantly,
the patient samples used for these experiments no longer
focus on infant ALL with MLL rearrangements, but reflect
a wider range of different ALL subtypes, including high-
risk Philadelphia chromosome-positive and BCR-ABL1-like
ALL, intermediate risk ALL with no known cytogenetic risk
factors and prognostically more favourable ALL with highEMBO Mol Med (2013) 5, 38–51  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 39
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40hyperdiploidy (Table 1). The ability of purified cells to initiate
the leukaemia was interrogated by intrafemoral injection into
immunodeficient NSG mice. Engrafted leukaemia mirrored the
original disease with enlarged spleens and infiltration of bone
marrow, liver, kidneys and the central nervous system and by
morphology and immunophenotype.
To summarize our experiments, blasts from eight primary
patient samples and five samples that have previously been
passaged through the mice (primografts; of which four were
unrelated to the primary samples) were sorted for low and high
expression of CD10 (Supporting Information Table S1). These
cells were injected intrafemorally into 134 NSG mice. Purified
blasts from six primary and all primograft samples engrafted.
Overall, both CD10high and CD10low populations from four of the
six primary and from each of the five primograft samples were
able to transfer the leukaemia onto the mice.
Similarly, blasts from 11 primary patient samples and
9 primografts (5 of these primografts derived from one of the
11 primary samples and 4 from unrelated samples) were sortedTable 1. Patient characteristics (NCI risk factor: age andwhite cell count, andm
Patient ID Presentation or relapse Cytogenetics
High hyperdiploidy
L754 Presentation High hyperdiploidy
L578 Relapse High hyperdiploidy
L812 Presentation High hyperdiploidy
L835 Presentation High hyperdiploidy
4917 Presentation High hyperdiploidy
Miscellaneous
L736 Presentation dic(9;20)(p13;q11)
L776 Presentation IGH2-CRLF2
L784 Presentation dic(9;20)(p13;q11)
L787 Presentation Normala,b
L803 Presentation Other
L825 Presentation Normala,b
L831 Presentation Faila,b
L833 Presentation Othera
L858 Presentation Normala,b
t(4;11)(q21;q23) or other MLL rearrangements
L826 Presentation t(4;11)
L876 Presentation t(4;11)
L727 Presentation t(11;19)(q23;p13.3)/MLL-E
t(9;22)(q34;q11) and BCR-ABL1-like
L4945 Presentation t(9;22)
L4951 Presentation t(9;22)
L4967 Presentation t(9;22)
L49101 Presentation t(9;22)
L49120 Presentation t(9;22)
2003 Presentation t(9;22)
2510 Presentation t(9;22)
4540a Presentation t(9;22)
8849 Presentation t(9;22)
EMCR1 Presentation BCR-ABL1-like
EMCR2 Presentation BCR-ABL1-like
Symbols used for additional molecular diagnostics are:
ano ETV6-RUNX1, no BCR-ABL1 and no MLL rearrangement;
bno IZKF deletion.
The codes for the experiments are:
1: transplantation of blasts sorted for CD10; 2: transplantation of blasts sorted f
limiting dilution; 5: CD20 limiting dilution; 6: CD34 limiting dilution; 7: expression
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.for low and high levels of CD20 expression and transplanted
into 400 immunodeficient NSG mice (Supporting Information
Table S2). Purified blasts from 10 primary and 7 primograft
samples engrafted. Overall, both CD20high and CD20low
populations from 8 of the 10 different primary and 6 of the 7
primograft samples were able to transfer the leukaemia onto the
mice. Extending our previous data (le Viseur et al, 2008), these
results confirm that in the majority of samples, representing a
wide range of B-ALL subtypes, all the different immunopheno-
types harbour leukaemia-propagating potential (Fig 1B–C).
Most importantly, we show that this phenotypic diversity of
leukaemia-propagating cells in B-ALL not only applies to cells
that have been passaged through mice, but also to primary
patient samples.
We have previously suggested a model of malleability
whereby different B-ALL populations sorted for a specific
surface marker could re-establish their phenotypic counterparts
in vivo. Here, we confirm this malleability for the B-cell
differentiation markers CD10, CD20 and CD34 in miceolecular-/cytogenetics) and experiments done with the respective samples
Age at presentation WCC (109) Experiments
3 142.0 2
6 4.1 1
2 81.9 7
4 5.8 2
9 13.4 3
2 71.9 2
4 50.8 2,7
18 52.2 1,6,8
19 11.6 7
18 99.7 1
14 122 3
16 6.1 1,2
14 162 2
14 27.0 3
<1 >50 3,8
<1 258 3
NL 1 94 2
7 82 2
15 184 1,2,3,5,6,8
13 230 2,3
3 55.9 1,2,3,8
16 66.2 1,3
15 179 3
16 44.2 1,2,5,8
2 71.0 6
20 360 1
4 264 1,2,3,4,5,6,8
5 97.5 1,2,3
or CD20; 3: transplantation at limiting dilution with unsorted cells; 4: CD10
arrays with cells sorted for CD34; 8: TERT expression in blasts sorted for CD34.
EMBO Mol Med (2013) 5, 38–51
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Figure 2. Phenotype of the re-established leukaemia after transplantation of purified B-ALL blast populations.
A. Engraftment of primografted CD10low and CD10high cells (patient L4951).
B. Engraftment of primografted CD20low and CD20high cells (patient EMCR1).
C. Engraftment of primografted CD34low and CD34high cells (patient EMCR1).
D. Engraftment of primary CD34low and CD34high cells (patient L784).transplanted with purified cells at low cell doses. Fig 2A–C
shows the flow analysis of leukaemias initiated by blasts sorted
for high and low expression of CD10, CD20 or CD34. All
populations were able to reconstitute their corresponding
population in vivo. The same picture was observed in mice
transplanted with cells purified from primary samples: CD20low
and CD20high as well as CD34low and CD34high cells (Fig 2D)
engrafted and were able to reproduce both populations.
Correlation of CD34 status with B-cell maturation-associated
gene expression signatures
One of the challenges in identifying different stages of B-cell
maturation in ALL is that expression of candidate B-cell
differentiation markers is often homogenous and does not
follow the coordinated pattern of expression seen in normal
B-cell development. The aberrant expression of surface markers
allows characterization of leukaemia-associated immunophe-
notypes that are used clinically to monitor disease (Irving et al,
2009). This may simply reflect the fact that the malignant
transformation has altered the normal lymphoid differentiation
programme and leukaemic stem cells may have a phenotype
different to that of their normal counterparts. However, the
inability to identify populations by marker combinations that
correspond to the well-defined stages of pro-B to pre-B
maturation raises the question about the relevance of theEMBO Mol Med (2013) 5, 38–51 expression levels of individual surface markers in a malignant
context.
We had previously shown that down-regulation of CD34
expression correlates with increased expression of candidate
B-cell differentiation genes (IRF4, MS4A1/CD20, IgH constant
locus, IgL k & l loci; le Viseur et al, 2008). To further investigate
whether, and to what extent, these populations mirror different
stages of normal B-cell differentiation, we compared gene
expression pattern of primary B-ALL cells sorted for high and
low expression of CD34 with those from CD34-positive human
haematopoietic stem and progenitor cells and cells of the B-
lymphoid lineage. We generated a 33-gene signature comprising
of the most consistently differentially expressed genes between
matched CD34high and CD34low leukaemic populations with
more than threefold differences in expression and >100-fold
difference in absolute intensity in each patient (Supporting
Information Table S3). Many genes in this signature including
BCL6, BACH2, MS4A/CD20 and several immunoglobulin genes
are known to be related to B-cell differentiation (Supporting
Information Fig S1A). The signature is notably devoid of
traditional leukemic self-renewal genes, e.g. the Hox gene
cluster. Principal component analysis (PCA) using this 33-gene
signature separated not only CD34high blasts from three different
B-ALL patients from the corresponding CD34low blasts, but
also normal CD34high haematopoietic stem and progenitor cells2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 41
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42from more differentiated B-cell stages. Consequently, CD34
status confers some real transcriptional differences between
subpopulations and these directly mirror and reflect lymphoid
maturation (Supporting Information Fig S1B). Gene Set
Enrichment Analysis (GSEA) ranking genes according to their
relative expression between CD34 subpopulations identified
many significantly enriched gene sets reflecting the transition
from immature to mature B cells (Supporting Information
Table S4). In a reverse experiment, we designed a customized
204-gene set containing genes differentially expressed between
normal pro-B and mature B cells (see the Materials andMethods
section) and applied it in GSEA and found that this gene set was
significantly enriched with respect to differential expression
between CD34high and CD34low B-ALL patient cells (Supporting
Information Fig S1C and Supporting Information Table S5),
providing further evidence that the CD34high and CD34low
subpopulations exhibit a real difference in expression, which
recapitulates to a measurable extent B-cell maturation and
support our model of malleability.
Regulatory networks and candidate stem cell genes in B-ALL
Our xenotransplantation data suggested that blasts sorted for
different surface markers should express key components of
cellular programmes that are essential for a sustained, if not
unlimited, proliferative potential.
The candidate gene we chose to test this hypothesis was
TERT, encoding the reverse transcriptase protein subunit of
telomerase. Telomerase restores telomeres and prevents
replicative senescence. TERT protein supports the maintenance
and expansion of normal and cancer stem cells both by
telomerase-dependent and -independent mechanisms (Stewart
et al, 2002). Moreover, our previous experiments showed that
its expression is induced and maintained by key leukaemic
fusion oncogenes, supporting its significant role in leukaemic
propagation (Gessner et al, 2010). Unfortunately, the low
expression levels of TERT may impede detection by gene
expression arrays. We, therefore, analysed expression of TERT
in CD34high and phenotypically more mature CD34low blasts
using quantitative RT-PCR. In the absence of telomerase-
independent alternative lengthening of telomeres, only blasts
with TERT expression should possess the ability for long-term
leukaemia propagation. As predicted, TERT mRNA levels in
normal human umbilical cord blood were approximately five
times higher in immature CD34high as compared with mature
CD34low cells. In contrast, there were no differences in TERT
expression between CD34high and CD34low leukaemic blasts
(Fig 3A).
In hierarchically organized murine AMLs, it has been
possible to define a stem cell-specific core transcriptional
programme expressed by the leukaemic stem cells, which
is responsible for the maintenance of the leukaemic stem cell
pool (Somervaille et al, 2009). In human AML, similar stem cell
expression programmes have been derived from phenotypically
defined candidate leukaemic stem cell populations (Gentles et al,
2010) and from cell populations with the ability to repopulate
xenotransplanted mice (Eppert et al, 2011). Both signatures have
been shown to correlate with clinical outcome. 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.To test our hypothesis that the regulatory network that
describes leukaemic propagation in B-ALL is different to the
stem cell programme in a hierarchical system, we performed a
PCA as before but this time using Eppert’s 42-gene (48-probe)
signature derived from candidate human AML stem cell
populations capable of repopulating immunodeficient mice
(Eppert et al, 2011). Component 1 represents the transition from
undifferentiated self-renewing haematopoietic progenitors to
lineage-restricted B lymphoid cells (Fig 3C). Component 2
represents the difference between leukaemic and normal cells.
As expected, this AML repopulating cell gene signature correctly
encapsulates the difference between immature Lin-CD34highC-
D38low and phenotypically more mature CD34low AML blasts
(Gentles et al, 2010) (purple and pink symbols), but fails to
distinguish CD34high from CD34low blasts in B-ALL (black and
white symbols), indicating the fundamental similarity of the two
populations in relation to expression of candidate stem cell
genes. The inability of stem cell signatures derived from AML
and normal haematopoiesis to distinguish between phenotypi-
cally more immature and more mature populations in ALL was
independently confirmed using a second AML leukaemic stem
cell signature (Gentles et al, 2010), a normal human
haematopoietic stem cell signature derived from NSG mouse
engrafting populations (Eppert et al, 2011) and a haematopoietic
‘self-renewal’ signature containing 59 genes (213 probes)
derived from the transcriptome of CD34high haematopoietic
stem/progenitor cells (Kim et al, 2009) (Supporting Information
Figs S2–S4). Unlike the analysis reflecting B-cell differentiation
(Supporting Information Fig S1), the PCAs using normal and
AML ‘stem cell’ signatures showed no distinction between
CD34high and CD34low B-ALL blast populations.
The uniform expression of candidate stem cell genes in
CD34high and CD34low B-ALL blast populations is also illustrated
in the heatmaps displaying selected probes from the self-
renewal signature described by Kim and co-workers (Kim et al,
2009; Fig 3B). As seen previously for TERT, several candidate
genes that have been implicated in the self-renewal of leukaemic
stem cells, such as MYB (Broske et al, 2009; Zuber et al, 2011),
are expressed both in immature and more mature B-ALL blasts
(Fig 3B). These analyses are consistent with the ability of the
different lymphoid populations to propagate the leukaemia in
immunodeficient mice. It should be noted that there are also
significant differences in expression of certain genes between
B-ALL blasts and normal hematopoietic and AML stem cell
populations (Fig 3B). Asmight be expected, given the absence of
MLL rearrangements in the ALL cohort, the most prominent
difference was the absence of expression of the HOX gene
cluster both in CD34high and CD34low B-ALL populations. These
differences in relation to the expression of self-renewal genes
are also reflected in the multicomponent analyses in which
neither the ALL blasts nor mature B lineage cells with the
potential for clonal expansion cluster together with candidate
AML stem cells (Fig 3C) or normal haematopoietic progenitor
cells (Fig 3C; Supporting Information Figs S2–S4).
In summary, this analysis shows that the two different
CD34low and CD34high leukaemia-propagating subpopulations
of B-ALL are indistinguishable with respect to several publishedEMBO Mol Med (2013) 5, 38–51
www.embomolmed.org Research Article
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Figure 3. Self-renewal gene expression in CD34high and CD34low B-ALL blasts.
A. Expression of TERT in CD34high and CD34low umbilical cord blood cells and leukaemic blasts. Umbilical cord blood shows higher expression of TERT in immature
CD34high cells whilst no difference is seen between immature CD34high and CD34low blasts. TERT expression in blasts is comparable with, or higher than, that in
CD34high umbilical cord blood progenitor cells. Expression values are 2-DCt using GAPDH as the reference gene. For purity of cells sorted for CD34 expression,
see Supporting Information Fig S6.
B. The PCA using a haematopoietic ‘‘self-renewal’’ signature containing 59 genes (213 probes) (Kim et al, 2009) also failed to separate CD34high and CD34low B-ALL
populations (Supporting Information Fig S4). Here, we show the heatmap of the expression of 41 selected probes from this ‘‘self-renewal’’ signature.
C. PCA plot generated using an AML ‘‘stem cell’’ signature (Eppert et al, 2011) that separates Lin-CD34highCD38low blasts (dark purple symbols) from more mature
CD34low (pink symbols) blasts in AML (Gentles et al, 2010) but fails to detect any significant differences in ‘‘self-renewal’’ gene expression amongst the
leukaemic subpopulations (black & white symbols) in B-ALL.
EMBO Mol Med (2013) 5, 38–51  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 43
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44self-renewal signatures and that the programme underlying
clonal expansion in B-ALL shows only a limited overlap with
the stem cell programme of normal haematopoietic and AML
stem cells.
High frequency of leukaemia-propagating cells across
phenotypically diverse blasts
If there is no hierarchy in B-ALL, as suggested by our functional
analysis, and given the right environmental/niche signals, in
principal every blast should have the potential to re-grow and
propagate the leukaemia. Even when taking the pro-apoptotic
effects of ex vivo handling of B-ALL blasts and the potentially
hostile xeno-environment in the mice into account, the
frequency of blasts with leukaemia-propagating potential
should be high and equal in the different populations.
Using improved, more immunodeficient mouse strains,
namely NSG mice, leading to increased sensitivity of the
xenograft model, there is now a more realistic opportunity to
estimate the frequency of human LPCs. Initial data on a limited
number of B-ALL samples (n¼ 5) had suggested that human
LPC may be more frequent than previously expected (Morisot
et al, 2010). To further investigate LPC frequencies in B-ALL we
transplanted blasts from 11 primary diagnostic B-ALL samples
that have been previously shown to engraft NSG mice and three
additional primografted B-ALL, both at limiting dilution. As
the strongest evidence for a rare, phenotypically immature
leukaemia stem cell population in B-ALL came from experi-
ments with Philadelphia chromosome-positive ALL (Castor
et al, 2005; Cobaleda et al, 2000; Hotfilder et al, 2005), we
primarily focused on patients, which were either BCR-ABL1-
positive (five patients) or demonstrated a BCR-ABL1-like
expression signature (two patients; Den Boer et al, 2009). To
test for broader applicability to other types of B-ALL, we also
included two patients with infant ALL/t(4;11) and three patients
with no known cytogenetic risk factors.
Two of the primary samples engrafted only at cell doses of
5 104 to 1 106 cells, while the remaining nine primary
leukaemias initiated the leukaemia with as few as 100–1000
cells (Table 2), with frequencies for leukaemia-propagating cells
ranging from 1:40 to 1:2900. Following passage through the
mice, the frequency of LPCs was even higher (1:10) and all
primograft specimens engrafted with as few as 10 transplanted
cells. These are much higher frequencies than reported in
previous studies, where less immunodeficient SCID or NOD/
SCID mice engrafted with 10,000–100,000 cells (Castor et al,
2005; Cobaleda et al, 2000; Cox et al, 2004; Hong et al, 2008; le
Viseur et al, 2008). This study confirms that in many B-ALL
patients, the frequency of blasts that are able to contribute to and
re-grow the leukaemia is likely to be high and that the ability
for clonal expansion may not be limited to a rare stem-like
population.
These data also challenged our previously published data
on the engraftment of phenotypically diverse blasts as those
transplants were done at high cell dose rather than at limiting
dilution and in retrospect, we therefore cannot exclude that few
contaminating blasts rather than the main purified population
engrafted the mice. We, therefore, interrogated the frequency of 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.leukaemia-propagating cells within the different subpopula-
tions. Overall, sorted populations from five different patients
(4 BCR-ABL1-positive or BCR-ABL1-like; 1 with no known
cytogenetic risk factors) were transplanted at limiting dilution
into mice (Table 2). For instance, primografted blasts from the
BCR-ABL1-like patient EMCR1 were sorted for either CD10,
CD20 or CD34 expression. All populations engrafted with an
estimated propagating cell frequency of 1:120 to 1:170
(confidence intervals ranging from 1:30 to 1:590). Counter-
intuitively, more immature CD20low-expressing cells from this
patient appeared to engraft less well with an estimated
propagating cell frequency of 1:1700 (confidence intervals
1:420–1:6700). However, only two mice engrafted in this
particular experiment and the confidence intervals overlap with
the respective results for the more mature CD20high blasts.
Importantly, there was no correlation between propagating cell
activity and CD20 status in three independent experiments with
primografted cells from two additional patients. Similarly, no
difference in the frequency of leukaemia-propagating cells was
detected between CD34high and CD34low population from three
out of four patients examined.
To exclude the possibility that these findings were an artefact
of clonal selection or adaptation to the xeno-environment
resulting from passage through the mice, we also assayed
primary blasts sorted for CD20 or CD34 expression and
transplanted at low cell dose. Again, all populations engrafted.
Both CD20high and CD20low primary cells from the previously
described patient, EMCR1, engrafted at a cell dose of 1500 cells
confirming that there was no difference in the leukaemia-
propagating potential of either population. Similarly, CD34high
and CD34low primary cells from dic(9;20)(p13;q11)-positive
patient L784 engrafted at similar frequency (1:660 to 1:930;
confidence intervals ranging from 1:230–1:2900). In only one
primary sample did the LPC frequency appear to be slightly
higher in the phenotypically more immature CD34high fraction
(1:840, confidence intervals 1:300–1:2300, as compared with
1:5000, confidence intervals 1:710–1:36,000). However, the
results for the CD34low fraction in this experiment are based on
only a single engrafted mouse and confidence intervals overlap.
Although we cannot exclude the presence of a stem cell
hierarchy in individual B-ALL patients when considering the
variablity of the in vivomouse model, our results demonstrate a
comparable frequency of leukaemia-propagating cells in all
populations tested.
Next, we tested the engraftment kinetics of the different
subpopulations. To this end, we determined the leukaemic
infiltration produced by CD10-, CD20- and CD34-sorted blasts
over time using sequential bone marrow punctures. In order to
achieve sufficient numbers of mice at each time point, all
engrafted mice transplanted with either 100–300 cells or 500–
3000 cells were pooled for this analysis. Each of the population
engrafted with similar kinetics (Fig 4).
Since it was unclear whether more ‘mature’ immunopheno-
types also have long-term self-renewal potential, we performed
serial transplantations with CD20high and CD34low leukaemic
blasts. In a proof-of-concept experiment, we were able to
maintain the leukaemia with ‘mature’ CD20high and CD34lowEMBO Mol Med (2013) 5, 38–51
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Table 2. Leukaemic engraftment at limiting dilution and quantification of LPC frequencies using unsorted B-ALL blasts and blasts sorted for expression
levels of CD10, CD20 and CD34
Patient ID Transplant Transplanted
blast
population
Number of engrafted mice/number
of transplanted mice injected with
Frequency of
leukaemia-propagating
cells estimate
(confidence intervals)
1000 cells 100 cells 10 cells
Primary transplants
EMCR1 Primary Unsorted 4/4 5/5 0/5 1:40 (1:16–112)
EMCR2 Primary Unsorted 2/3 0/5 0/5 1:1200 (1:300–4700)
L858 Primary Unsorted 4/5 2/5 0/5 1:460 (1:180–1200)
L876 Primary Unsorted 4/4 4/5 0/5 1:80 (1:30–210)
2003 Primary Unsorted 1/3 0/4 0/5 1:2900 (1:420–20,000)
4917 Primary Unsorted 1/3 0/4 0/5 1:2900 (1:420–20,000)
L4967 Primary Unsorted 4/4 5/5 0/5 1:40 (1:16–110)
L49120 Primary Unsorted 1/4 1/5 0/5 1:1900 (1:540–6600)
L49101 Primary Unsorted 2/4 0/4 0/4 1:950 (1:240–3700)
Secondary/tertiary transplants (primografts)
L4951 Secondary Unsorted 6/6 10/10 5/8 1:10 (1:4–25)
L49101 Secondary Unsorted 4/4 5/5 4/5 1:6 (1:2–18)
L4967 Tertiary Unsorted 3/3 5/5 3/5 1:11 (1:3–35)
CD10
EMCR1 Secondary CD10high 4/4 2/4 0/5 1:170 (1:47–590)
CD10low 4/4 2/3 0/5 1:120 (1:30–460)
CD20
EMCR1 Primary CD20high 4/4a – – Unable to calculate
CD20low 4/4a – – Unable to calculate
EMCR1 Secondary CD20high 4/4 2/4 0/5 1:170 (1:47–590)
CD20low 2/4 0/4 0/5 1:1700 (1:420–6700)
2510 Secondary CD20high 2/4 0/4 – 1:4900 (1:1200–20,000)
CD20low 4/4 1/4 – 1:780 (1:230–2700)
L4951 Secondary CD20high 11/11 5/5 – Unable to calculate
CD20low 10/11 6/6 – Unable to calculate
Tertiary CD20high – 3/3 0/4 1:140 (1:25–740)
CD20low – 3/3 0/4 1:140 (1:25–740)
CD34
L784 Primary CD34high 3/4 0/5 0/5 1:930 (1:300–2.900)
CD34low 3/4 1/5 0/6 1:660 (1:230–1900)
4540a Primary CD34high 2/5 3/5 0/4 1:840 (1:300–2.300)
CD34low 1/5 0/5 0/5 1:5.000 (1:710–36.000)
EMCR1 Secondary CD34high 4/4 1/5 3/5 1:120 (1:40–360)
CD34low 4/4 2/5 1/5 1:140 (1:46–450)
L4951 Tertiary CD34high 3/3 5/5 5/6 1:6 (1:2–15)
CD34low 4/4 5/5 4/5 1:6 (1:2–1:18)
aPrimary cells from patient EMCR1 were transplanted at a cell dose of 1500 cells/mouse. Group sizes >5 indicate pooled data from several transplantation
experiments.blasts over at least five serial transplantations (Supporting
Information Fig S5). Ten thousand primary cells from BCR-
ABL1-positive patient L4951, sorted for high CD20 expression,
established the disease in primary mice. One thousand unsorted
blasts from the primary mice re-initiated the leukaemia in
secondarymice. One hundred blasts sorted for low expression of
CD34 transferred the leukaemia onto tertiary mice and unsorted
blasts from these tertiary mice have now been passaged through
two more generations of mice, clearly demonstrating long-term
self-renewal of these ‘mature’ B-ALL blasts. In an additional
experiment, 2 104 CD20high blasts engrafted secondary mice
and 2 103 CD20high cells purified from the secondary mice
engrafted tertiary mice.EMBO Mol Med (2013) 5, 38–51 In summary, here we provide quantitative data on the
frequency and engraftment kinetics of leukaemia-propagating
cells in a range of phenotypically diverse blast cell populations
fromboth primary and primografted samples, demonstrating that
each of the human populations reads out in this NSGmouse assay
with similar frequencies of leukaemia-propagating cells, similar
engraftment kinetics and with long-term engraftment potential.DISCUSSION
Different models have been applied to explain the heterogeneity
within a given tumour with respect to the ability of individual2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 45
Research Article www.embomolmed.org
Acute lymphoblastic leukaemia propagating cells
Figure 4. Engraftment kinetics of purified B-ALL
subpopulation as assessed by sequential bone
marrow punctures. Mice from all limiting dilution
experiments were pooled, as the number of mice in
each individual transplantation experiment was too
low for the analysis. Data are mean percentage of
engraftment with bars showing standard error of the
mean.
A,B. Engraftment kinetics of CD10high and CD10low
cells after transplantation of 100 (n¼ 4) or
1000–2000 blasts (n 4).
C,D. Engraftment kinetics of CD20high and CD20low
cells after transplantation of 100–300 (n 8)
or 500–3000 blasts (n 21).
E,F. Engraftment kinetics of CD34high and CD34low
cells after transplantation of 100 (n 6, last
points n¼2 for CD34high and n¼ 3 for CD34low)
or 1000 blasts (n9).
46tumour cells to maintain and re-establish the disease (Bomken
et al, 2010; Magee et al, 2012). The hierarchical stem cell model
predicts that a tumour is maintained by a distinct, immature
and typically rare cancer-propagating stem cell. The balance
between self-renewal and differentiation is tightly regulated and
loss of ‘stemness’ is imposed on the progeny by progressive
epigenetic silencing of self-renewal genes (Broske et al, 2009). A
hierarchical cancer stem cell model was first shown to apply to
AML (Bonnet & Dick, 1997; Lapidot et al, 1994) and since then
has been used to describe and identify cancer stem cells in a
wide range of malignancies (Dick, 2008). However, the question
has been raised of whether the hierarchical stem cell model
applies to all cancer types (Kelly et al, 2007) and in a murine
BCR-ABL-driven ALL model nearly every blast had been shown
to have leukaemia-propagating potential (Williams et al, 2007).
Studies with human melanoma cells also demonstrated that
as many as one in four cells, irrespective of their phenotype,
possess the ability to propagate the tumour (Quintana et al,
2008, 2010). This is consistent with the alternative, stochastic
stem cell model in which the ability to self-renew represents a
functional cellular phenotype. Execution of the ‘stemness’
programme is dependent on endogenous and exogenous (micro- 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.environmental) signals, but the potential is present in any
tumour cell.
In our previous experiments (le Viseur et al, 2008), we had
demonstrated leukaemia-propagating activity in a wide range
of phenotypically diverse blast populations, questioning the
applicability of the hierarchical stem cell model for human B
lineage acute lymphoblastic leukaemia. Although these data
contradicted a number of studies investigating the phenotype of
leukaemia stem cells in B-ALL (Cobaleda et al, 2000; Cox et al,
2004, 2009; Hong et al, 2008), more recent studies using
improved mouse models (see discussion below) reached very
similar conclusions (Diamanti et al, 2012; Kong et al, 2008;
Morisot et al, 2010).
The differences between our model, suggesting a lack of a
leukaemia stem cell hierarchy, and previous studies suggesting
the presence of a distinct leukaemic stem cell population
(Cobaleda et al, 2000; Cox et al, 2004, 2009; Hong et al, 2008) are
most likely due to differences in the mouse models. Taussig and
co-workers demonstrated that even in severely immunodefi-
cient mice, antibody-coated human cells can be cleared by the
residual innate immune system (Taussig et al, 2008). Other
modifications to the xenograft model, such as the use of differentEMBO Mol Med (2013) 5, 38–51
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transplantation (Taussig et al, 2008), will also affect which cells
are able to read out as stem cells and failure to engraft may have
explanations other than lack of stemness (Vormoor, 2009).
Although an increasing body of data has been published,
which supports our model, key questions remained unan-
swered. Our previous studies were biased towards high-risk
infant ALL, allowing the possibility that our model may not be
widely applicable to other types of ALL. More importantly, our
xenotransplants primarily used primograft samples and, based
on the experience in xenografted T-ALL (Chiu et al, 2010), there
was concern that the phenotype of cells able to propagate the
leukaemia may be unstable and change following passage
through the mice. To address these concerns, we have now used
primary in addition to primograft samples, samples from
patients reflecting a wider range of acute B lymphoblastic
leukaemia (B-ALL) subtypes (Table 1) and purified blasts based
on the expression of additional B-cell differentiation markers.
Our experiments demonstrate that this model is indeed more
widely applicable to B-ALL, including primary patient samples,
and we show that cells with leukaemia-propagating potential
are present in phenotypically diverse blast cell populations,
specifically in CD10low/high, CD20low/high and CD34low/high cells.
One of the key limitations of previous experiments was
the lack of quantitative data on the frequency of LPCs in
unseparated primary blasts and in the different blast popula-
tions. Our model suggests that leukaemia-propagating activity is
not limited to a phenotypically rare cell population but may be
quite frequent. Indeed, we now show that the frequency of B-
ALL blasts able to initiate human leukaemia in immunodeficient
NSGmice is high, with many primary leukaemias able to engraft
with as few as 100 cells. Propagating cell frequencies increase
further after passage through the mice, most likely due to
selection of clones better adapted to the murine microenviron-
ment (Clappier et al, 2011). Growth and growth kinetics of B-
ALL in immunodeficient mice have indeed been correlated with
expression of apoptosis resistance genes (Meyer et al, 2011).
This suggests that in patients—where there is no xenograft
barrier and no ex vivo manipulation—the frequency of blasts
that are able to contribute to and re-grow the leukaemia is likely
to be higher than that assessed in a xeno-environment. Similar
studies reporting a high frequency of leukaemia-propagating
cells in five primary samples (Morisot et al, 2010) and in
primografts (Schmitz et al, 2011) have also recently been
described by others.
Importantly, we demonstrate here that propagating cell
frequencies and engraftment kinetics are similar across a wide
range of populations, including immunophenotypically more
mature blasts, at least within a cohort biased towards
Philadelphia-chromosome-positive ALL. These experiments
are consistent with the stochastic stem cell model in these
patients. Together with the demonstration of a high frequency of
leukaemia-propagating cells in non-high-risk patients (L784,
L858 and 4917) and the comparable engraftment of different
lymphoid subpopulations from a wide range of patients, these
data suggest that the lack of a stem cell hierarchy may be a more
universal feature of B-ALL.EMBO Mol Med (2013) 5, 38–51 Our xenotransplantation data suggested that blasts sorted for
different surface markers should express key components of
cellular programmes that are essential for a high, if not
unlimited, proliferative potential. The candidate gene we chose
to test this hypothesis was TERT, which controls self-renewal
of normal and cancer stem cells, and whose expression is
maintained by key leukaemic fusion oncogenes supporting
its essential role in leukaemic propagation (Gessner et al, 2010).
As predicted, quantitative RT-PCR analysis revealed that there
were no differences in TERT expression between CD34high and
CD34low leukaemic blasts. This is similar to normal B-cell
development: in line with the high proliferative potential,
lymphocytes are the only cellular compartment in humans in
which TERT expression is maintained even during the late
stages of differentiation and can be up-regulated with activation
and proliferation (Liu et al, 1999; Lobetti-Bodoni et al, 2010;
Son et al, 2003). Notably, none of gene expression signatures
generated from AML or normal cells with self-renewal potential
(Eppert et al, 2011; Gentles et al, 2010; Kim et al, 2009)
distinguished CD34high from CD34low blasts in B-ALL, indicating
their similarity in relation to expression of candidate stem cell
genes. These expression data are consistent with ourmodel that,
unlike the myeloid lineage, B-ALL shows no dissociation
between self-renewal and differentiation (Fig 5). Notably, one
of the early pioneers of stem cell biology, the late Dr Ernest
McCulloch, stated that ‘a minimum conclusion to be reached
from the comparison of myelopoiesis and lymphopoiesis is that
a firm linkage between differentiation and loss of proliferative
capacity is not a general characteristic of hemopoiesis’
(McCulloch, 1983). Normal mature lymphoid cells maintain
their ability to clonally expand—a characteristic, which is a core
element of the lymphocyte response to re-exposure to antigen.
Lymphoid cells can therefore be considered unipotent stem cells
and we show here that this may also apply to malignant blasts in
B lineage acute leukaemia.
Amodel of clonal evolution has recently been proposed for B-
ALL (Anderson et al, 2011; Notta et al, 2011). Although both the
hierarchical and the stochastic stem cell model are compatible
with clonal evolution, the high frequency of phenotypically
diverse leukaemia-propagating cells as described here (stochas-
tic model) will more easily facilitate clonal evolution and the
generation of clonal complexity.
In summary, our experiments demonstrate that, consistent
with the stochastic model, many lymphoid blasts with diverse
immunophenotypes can clonally expand and propagate the
leukaemia. Unravelling the mechanisms of clonal expansion
will provide novel therapeutic targets that may not only be
exploited for the treatment of B-ALL, but may also be applicable
to other lymphoid malignancies and autoimmunity.MATERIALS AND METHODS
Patient samples
Bone marrow and peripheral blood samples were collected as part of
initial diagnostic investigations. Written informed consent was
obtained from patients and/or legal guardians according to protocols2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 47
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Figure 5. Models for regulation of self-renewal, proliferation and differentiation in normal haematopoietic stem cells and acute myeloid leukaemia as
compared with acute lymphoblastic leukaemia.
A. In normal haematopoietic stem cells and AML, self-renewal is tightly regulated by a differentiation-dependent loss of self-renewal.
B. In B-ALL, clonal expansion is tightly regulated by the dependence of positive survival and proliferation signals. Without those lymphoid blasts undergo
apoptosis.
48approved by the corresponding review boards. Patient samples from
the UK that were stored before September 2006 were exempt from
specific consent for research by the Human Tissue Act. Anonymized
umbilical cord blood specimens, stored with consent for research, were
obtained from the Newcastle Umbilical Cord Blood Bank, Newcastle
University.
Flow cytometry
Mononuclear cells from thawed diagnostic bone marrow or peripheral
blood samples and freshly recovered bone marrow from transplanted
mice were analysed by 5-colour flow cytometry. Samples were
collected into RPMI 1640 medium containing 10% FCS and re-
suspended in phosphate-buffered saline (PBS) containing 0.2% bovine
serum albumin (PBSA). Diagnostic samples were incubated with
saturating amounts of monoclonal antibodies (BD Biosciences, Oxford,
UK) to human surface proteins of interest in a total volume of 200ml
for 20min at room temperature in the dark. Antibodies used were:
anti-CD10 FITC (clone HI10a); anti-CD19 PE (clone SJ25C1); anti-
CD20 PerCP-Cy5.5 (clone L27); anti-CD38 PE-Cy7 (clone HB-7); anti-
CD34 APC (clone 8G12). For bone marrow samples harvested from
mice, anti-CD38 PE-Cy7 was exchanged for murine anti-TER119
PE-Cy7 and murine anti-CD45 PE-Cy7 (clone 30-F11) to exclude
contaminating murine cells. Stained samples were washed twice and
resuspended in 400ml PBSA for analysis. All flow cytometric analyses
were performed on a FACSCanto II flow cytometer (BD Biosciences)
using FACSDiva analysis software v6.1. Cell sorting was performed on
a FACSVantage SE cell sorter (BD Biosciences) using CellQuest Pro
software. Staining for cell sorting was performed as described above
using anti-CD19 PE, anti-CD10 FITC, anti-CD20 FITC (clone L27) or
anti-CD34 FITC (clone 8G12). Mean purities of the sorted populations
were: CD10high—98%, CD10low—99%, CD20high—95%, CD20low—
99%, CD34high—97% and CD34low—99%.
Animal model
All transplantation experiments were performed using NSG mice
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice; Jackson Laboratories, Bar 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Harbor, ME, USA) (Shultz et al, 2005). All handling and experimental
manipulation of these animals was performed in a laminar flow hood
using aseptic techniques. Mice used for transplantation were at least
6 weeks of age (body weight 20–30 g). Prior to transplantation, mice
were anaesthetized with 2.5–5% isoflurane in 1.5 L/min of oxygen,
followed by subcutaneous administration of Carprofen (Rimadyl,
Pfizer, UK) 5mg/kg. The femur was punctured with a 27G or 30G
needle (BD Biosciences) followed by injection of up to 30ml of cell
suspension using a 0.5ml insulin syringe (30G). To obtain bone
marrow aspirates, the femur was punctured with a 25G needle,
followed by aspiration using a fresh 25G needle into a syringe filled
with 400ml of RPMI 1640 medium containing 20% FCS. The health
status of the mice was checked clinically on a daily basis and all mice
were weighed on a weekly basis. As soon as mice developed clinical
signs of leukaemia development or had a weight loss of more than
20%, they were humanely killed. Due to the normal variability of the
xenograft assay and depending on the number of viable leukaemic
blasts available we aimed for group sizes of 3–5 animals per purified
population, patient and cell dose. All animal experiments were
approved under the UK Home Office licence (PPL 60/3846).
Calculation of propagating cell frequencies
LPC frequencies were calculated using the open access programme
ELDA, http://bioinf.wehi.edu.au/software/elda/ (Hu & Smyth, 2009). For
the purpose of this study, the analysis is based on the assumption that
the frequency of propagating cells in the different inocula follows the
Poisson distribution with one cell being sufficient to re-grow the
leukaemia (Poisson single hit model).
TERT expression in sorted blast populations and normal
umbilical cord blood
Leukaemic CD34low and CD34high populations were sorted as
described. Thawed umbilical cord blood was washed in 500ml
RPMI 1640 supplemented with 10% FCS and resuspended in 50ml
DNase buffer (0.5mM MgCl2, 1mM CaCl2, 0.5% w/v PBSA). Cells
were incubated with 5000U DNase I (Sigma) for 45min atEMBO Mol Med (2013) 5, 38–51
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The paper explained
PROBLEM:
The hierarchical stem cell model predicts that a tumour is
maintained by a distinct cancer propagating stem cell, which
therefore represents the principal target of any curative treatment.
RESULTS:
Here, we show that propagating cells in acute lymphoblastic
leukaemia cannot be enriched by purification based on a range of
B-cell maturation markers. All purified populations engraft with
similar and high frequency and with similar kinetics and
furthermore each population is able to replenish the others.
These data are consistent with the lack of a stem cell hierarchy in
acute B lymphoblastic leukaemia and, in principle, all blasts may
have the ability to propagate the leukaemia.
IMPACT:
Unravelling the mechanisms, which regulate and drive clonal
expansion in malignant lymphoid blasts, will provide new
therapeutic targets that are likely to be relevant not only for rare
childhood leukaemia but may also apply to other lymphoid
malignancies and autoimmunity.room temperature. Washed cells were labelled with saturating
amounts of FcR blocking reagent and MACS anti-CD34 microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). CD34high cells were
purified by serial passage down two LS positive selection
columns according to the manufacturer’s instructions. Unlabeled
flow-through cells were collected to provide the CD34 negative
population. RNA was isolated from sorted populations using an
RNeasy kit according to the manufacturer’s instructions (Qiagen,
Hilden, Germany).
RNA was reverse transcribed using RevertAidTM H Minus First Strand
cDNA Synthesis Kit (Fermentas). The qRT PCR reaction was performed
in 10ml on a 384-well plate using 20% v/v cDNA, 50% v/v 2
Platinum SYBR QPCR Supermix with ROX (Invitrogen) and 0.3mM
primers: TBP Fw: 50—CCT AAA GAC CAT TGC ACT TCG T—30 , Re: 50—
GTT CGT GGC TCT CTT ATC CTC A—30 ; CD34 Fw: 50—AAA GCA CCA ATC
TGA CCT GAA A—30 , Re: 50—CGA GGT GAC CAG TGC AAT CA—30 ; TERT
Fw: 50—GGA GAA CAA GCT GTT TGC GG—30 , Re: 50—AGG TTT TCG
CGT GGG TGA G—30 . Reaction conditions were: 2min at 508C, 10min
at 958C followed by 40 cycles of 15 s at 958C, 1min at 608C followed
by 15 s at 958C, 15 s at 608C and 15 s at 958C. Quantitative analysis
was performed using a 7900HT Sequence Detection System (Applied
Biosystems). Data analysis was performed using SDS 2.2 software
(Applied Biosystems) by DCt comparison, using GAPDH as a reference
transcript.
Expression profiling of CD34low and CD34high blasts
Diagnostic patient bone marrow was sorted for CD34high/low
expression as previously described (le Viseur et al, 2008). Isolated
RNA was taken forward for expression microarray analysis using the
Affymetrix Genechip HG-U133 Plus 2.0 array (GeneService Ltd.). Data
are available at ArrayExpress (http://www.ebi.ac.uk/microarray-as/aer/)
under the accession number E-MEXP-1522.
CEL files from Affymetrix HGU133plus2 profiles representing the
different haematopoietic subpopulations were taken from GEO Series
GSE8023 (Krejci et al, 2008), GSE17186 (Suryani et al, 2010),
GSE19599 (Andersson et al, 2007), GSE24006 (Gentles et al, 2010)
and normalized along with profiles from CD34 sorted cells from
patients L787, L812 and L776 using gc Robust Multiarray Average
(gcRMA). Two sets of genes were selected. The first reflectedEMBO Mol Med (2013) 5, 38–51 hematopoietic ‘self-renewal’ genes (a 57 gene 231 probe signature
taken from (Kim et al, 2009) and an AML LSC signature from (Eppert
et al, 2011). The second consisted of 33 probes, highly differentially
expressed between CD34high and CD34low subpopulations showing
greater than threefold difference in expression and greater than
100-fold difference in absolute intensity in each patient. PCA was
performed using R or TMEV package (http://www.tm4.org/mev/)
where appropriate. Heatmaps were generated using Genepattern
(www.broadinstitute.org/cancer/software/genepattern/). GSEA was
performed using the stand alone application www.broadinstitute.
org/gsea/ using MSigDB C2v3 geneset database with a custom geneset
added containing 204 genes at least threefold mean differentially
expressed between pro-B cells and mature B-cell expression profiles
as found in GSE19599.Author contributions
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